A Monoclonal Antibody to PACAP for Migraine Prevention

单克隆抗体 偏头痛 医学 抗体 免疫学 内科学
作者
Messoud Ashina,Ravinder Phul,Melanie Khodaie,Elin Löf,Ioana Florea
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:391 (9): 800-809 被引量:121
标识
DOI:10.1056/nejmoa2314577
摘要

BACKGROUND: Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) is a new avenue for treating migraine. The efficacy and safety of intravenous Lu AG09222, a humanized monoclonal antibody directed against the PACAP ligand, for migraine prevention are unclear. METHODS: In a phase 2, double-blind, randomized, placebo-controlled trial, we enrolled adult participants (18 to 65 years of age) with migraine for whom two to four previous preventive treatments had failed to provide a benefit. The trial included a 4-week treatment period and an 8-week follow-up period. Participants were randomly assigned in a 2:1:2 ratio to receive a single-dose baseline infusion of 750 mg of Lu AG09222, 100 mg of Lu AG09222, or placebo. The primary end point was the mean change from baseline in the number of migraine days per month, during weeks 1 through 4, in the Lu AG09222 750-mg group as compared with the placebo group. RESULTS: Of 237 participants enrolled, 97 received 750 mg of Lu AG09222, 46 received 100 mg of Lu AG09222, and 94 received placebo. The mean number of baseline migraine days per month was 16.7 in the overall population, and the mean change from baseline over weeks 1 through 4 was -6.2 days in the Lu AG09222 750-mg group, as compared with -4.2 days in the placebo group (difference, -2.0 days; 95% confidence interval, -3.8 to -0.3; P = 0.02). Adverse events with a higher incidence in the Lu AG09222 750-mg group than in the placebo group during the 12-week observation period included coronavirus disease 2019 (7% vs. 3%), nasopharyngitis (7% vs. 4%), and fatigue (5% vs. 1%). CONCLUSIONS: In a phase 2 trial, a single intravenous infusion of 750 mg of Lu AG09222 showed superiority over placebo in reducing migraine frequency over the subsequent 4 weeks. (Funded by H. Lundbeck; HOPE ClinicalTrials.gov number, NCT05133323.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lemonhead的应助被cocoxue采纳,获得30
刚刚
huhu发布了新的文献求助10
刚刚
英俊的铭的应助被18276995909采纳,获得10
刚刚
MYSELF发布了新的文献求助30
刚刚
刚刚
ahusyz完成签到,获得积分10
刚刚
温暖砖头发布了新的文献求助10
刚刚
wanci的应助被牧百川采纳,获得10
刚刚
yunjian1583发布了新的文献求助10
1秒前
1秒前
Lucas的应助被万幸鹿采纳,获得10
1秒前
涛哥发布了新的文献求助10
1秒前
默默的恶天完成签到,获得积分20
1秒前
1秒前
花花发布了新的文献求助10
1秒前
1秒前
哈机密发布了新的文献求助10
1秒前
2秒前
beibei发布了新的文献求助10
2秒前
Qw完成签到 ,获得积分10
2秒前
2秒前
小二郎的应助被believe采纳,获得10
2秒前
3秒前
852的应助被机灵幻天采纳,获得10
3秒前
陶醉晓凡发布了新的文献求助10
3秒前
yyf发布了新的文献求助30
3秒前
科研通AI6.4的应助被南宫无血采纳,获得10
4秒前
4秒前
ldy发布了新的文献求助10
4秒前
脑洞疼的应助被Gallavich采纳,获得30
5秒前
啊嘞哇塞完成签到,获得积分20
5秒前
慕青的应助被优秀毛衣采纳,获得10
5秒前
5秒前
5秒前
白门小强完成签到,获得积分10
5秒前
BaiXiaoYu完成签到,获得积分10
5秒前
6秒前
方正发布了新的文献求助10
6秒前
可爱的函函的应助被yelinxu采纳,获得10
7秒前
时尚凌雪完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182977
求助须知:如何正确求助?哪些是违规求助? 9572322
关于积分的说明 21824168
捐赠科研通 7779612
什么是DOI,文献DOI怎么找? 3433774
关于科研通互助平台的介绍 2558024
邀请新用户注册赠送积分活动 2479971